Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOP study: ALX1-11 in Postmenopausal Osteoporosis
NCT00172081Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2000
- Primary completion
- Nov 2003
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in postmenopausal osteoporosis comparing Preos with Placebo (2 arms). Primary endpoint: Incidence of new and/or worsened thoracic and lumbar vertebral fractures at 18 months. Started Apr 2000; status: completed.
02
Drugs
parathyroid hormone 1-84
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT00172081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00172081.